Category Archives: Neuroscience

Gereau honored for mentorship and training in neuroscience research – Washington University School of Medicine in St. Louis

Visit the News Hub

Recognized with Landis Award from National Institute of Neurological Disorders and Stroke

Gereau

Robert W. Gereau IV, PhD, the Dr. Seymour and Rose T. Brown Professor and vice chair for research in the Department of Anesthesiology, has received the Landis Award for Outstanding Mentorship from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The award, one of six presented this year, is named for Story Landis, PhD, who directed the NINDS from 2003-14 and established programs to promote the development of neuroscientists.

Gereau, also a professor of neuroscience and director of the Washington University Pain Center, studies the molecular mechanisms involved in pain sensation. Much of the work in which he mentors pre- and postdoctoral trainees includes studies in optogenetics, which uses light to activate or deactivate nerve cells that transmit pain signals from the periphery of the body to the brain. The ability to visualize how neural circuits connect and transmit pain signals could allow for the development of new treatments and therapies for pain.

Nominations for the Landis Award are submitted by current and former trainees, and award recipients receive $100,000 to supplement their existing NINDS grant support and help subsidize the career advancement of trainees.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more from the original source:
Gereau honored for mentorship and training in neuroscience research - Washington University School of Medicine in St. Louis

Neuroscience Antibodies & Assays Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 – Bulletin Line

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Neuroscience Antibodies & Assays Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Neuroscience Antibodies & Assays Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Neuroscience Antibodies & Assays market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Global Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Neuroscience Antibodies & Assays Market are:

Competitive Landscape of the Neuroscience Antibodies & Assays Market:

The market for the Neuroscience Antibodies & Assays industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Global Neuroscience Antibodies & Assays Market, By Product

Consumables Instruments

Global Neuroscience Antibodies & Assays Market, By Technology

Clinical Chemistry Immunoassays/Immunochemistry Molecular Diagnostics Other Technologies

Global Neuroscience Antibodies & Assays Market, By Application

Drug Discovery & Development Research in Vitro Diagnostics

Global Neuroscience Antibodies & Assays Market, By End-User

Hospitals & Diagnostics Centers Pharmaceutical & Biotechnology Companies Academic & Research Institutes

Regional Analysis of Neuroscience Antibodies & Assays Market:

A brief overview of the regional landscape:

From a geographical perspective, the Neuroscience Antibodies & Assays Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Neuroscience Antibodies & Assays Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

View original post here:
Neuroscience Antibodies & Assays Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Potential Impact of COVID-19 Pandemic on Global Neuroscience Antibodies and Assays Market Report PDF 2020 Key Companies Thermo Fisher, Abcam, Bio Rad,…

Report is a detailed study of the Neuroscience Antibodies and Assays market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Neuroscience Antibodies and Assays market is to help making reliable strategic decisions regarding the opportunities in Neuroscience Antibodies and Assays market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/medical-devicesconsumables/neuroscience-antibodies-and-assays-market-report

Global and Regional Neuroscience Antibodies and Assays Market Segmentation by Type: Consumables, Instruments

Global Neuroscience Antibodies and Assays Market Segmentation by Applications: Pharmaceutical& Biotechnology Companies, Academic& Research Institutes, Hospitals& Diagnostic Centers

Major Market Players with an in-depth analysis: Thermo Fisher, Abcam, Bio Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens

Request Free Sample Copy of Neuroscience Antibodies and Assays Market Research Report@ https://cognitivemarketresearch.com/medical-devicesconsumables/neuroscience-antibodies-and-assays-market-report#download_report

The Neuroscience Antibodies and Assays market report offers the current state of the market around the world. The report starts with the market outline and key components of the Neuroscience Antibodies and Assays market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Neuroscience Antibodies and Assays market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Neuroscience Antibodies and Assays business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Neuroscience Antibodies and Assays Market Report 2020 (Coronavirus Impact Analysis on Neuroscience Antibodies and Assays Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Neuroscience Antibodies and Assays market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Neuroscience Antibodies and Assays product has been completely profiled along with their SWOT. Some of the key players include Thermo Fisher, Abcam, Bio Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Neuroscience Antibodies and Assays market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Neuroscience Antibodies and Assays North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/medical-devicesconsumables/neuroscience-antibodies-and-assays-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, SegmentationOverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: Complete profiling and analysis of ManufacturersChapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expensesChapter 10: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 11: Marketing Strategy Analysis, Distributors/TradersChapter 12: Market Effect Factors AnalysisChapter 13: Market ForecastChapter 14: Neuroscience Antibodies and Assays Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/medical-devicesconsumables/neuroscience-antibodies-and-assays-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/neuroscience-antibodies-and-assays-market-report

The rest is here:
Potential Impact of COVID-19 Pandemic on Global Neuroscience Antibodies and Assays Market Report PDF 2020 Key Companies Thermo Fisher, Abcam, Bio Rad,...

AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board -…

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the expansion of its Scientific Advisory Board, appointing esteemed neuroscientist Robert Malenka, M.D., Ph.D., as well as experts in the development of neuroimmunology and T-cell therapeutics, Adam Boxer, M.D., Ph.D., Vijay Kuchroo, D.V.M., Ph.D., and Megan Levings, Ph.D., who have joined the AZTherapies SAB following the companys acquisition of Smith Therapeutics in October 2019.

We are very pleased to welcome these neuro-immunology leaders to our Scientific Advisory Board, as we are all committed to advancing efforts to slow down or halt the progression of neurodegenerative diseases by targeting neuroinflammation as the main cause of progressive neural damage, and declining cognition and function, said David R. Elmaleh, Ph.D., AZTherapies Founder, CEO, and Chairman. Each of our new board members brings unique expertise relevant to our pipeline whether it be our Phase 3 program in early Alzheimers disease, our progressing candidate for the treatment of ALS and post-ischemic stroke cognitive impairment, or our novel biologic approach using specifically engineered immunosuppressive CAR-T regulatory (Treg) cells to treat neurodegenerative disease and I look forward to working together to achieve our common goals.

Philip Ashton-Rickardt, Ph.D., Senior Vice President, Immunology at AZTherapies also commented on the appointments: I am thrilled that the SAB members from Smith have agreed to stay on to support our efforts in the development of CAR-Tregs to restore a healthy balance of inflammatory and regulatory cells in the brain. Since last fall, we have continued to advance this innovative program through pre-clinical development, and now anticipate initial in vitro and in vivo proof of concept across several models of neurodegenerative disease later this year.

Dr. Malenka is Deputy Director of the Wu Tsai Neurosciences Institute and Associate Chair of the Department of Psychiatry and Behavioral Science at Stanford University, while also serving as the Pritzker Professor of Psychiatry & Behavioral Sciences. Recognized as a world leader in the field of synapse biology, his work has resulted in more than 250 scientific publications. Dr. Malenka is an elected member of both the National Academy of Sciences and the National Academy of Medicine as well as the American Academy of Arts and Sciences. He received a B.A., summa cum laude, from Harvard College and an M.D. and a Ph.D. in neuroscience from Stanford University School of Medicine.

Dr. Boxer is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF) and directs UCSFs Neurosciences Clinical Research Unit and the Alzheimers Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxers research is focused on developing new treatments and biomarkers for neurodegenerative diseases. He is the principal investigator of the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Clinical Research Consortium, while also leading the FTD Treatment Study Group, which is looking to speed the development of new therapies for FTD. The author of more than 150 scientific publications, Dr. Boxer received his medical and doctorate degrees at New York University Medical Center.

Dr. Kuchroo is the Samuel L. Wasserstrom professor of neurology at Harvard Medical School, and a senior scientist at Brigham and Womens Hospital. He is also a member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Womens Hospital. Dr. Kuchroo obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India, and subsequently specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. He is the recipient of the Fred Z. Eager Research Prize, the Javits Neuroscience Award by the NIH, the Ranbaxy Prize in Medical Research, the Nobel Laureate Peter Doherty Lecture/Prize, and was named Distinguished Eberly Lecturer.

Dr. Levings is Professor, Department of Surgery and School of Biomedical Engineering, Faculty of Medicine at the University of British Columbia, Investigator at BC Childrens Hospital Research Institute, Lead, Childhood Diseases Research Theme, and an Associate Member of the Department of Microbiology and Immunology. She is internationally recognized in the field of human immunology and currently chairs the Federation of Clinical Immunology Societies Centers' of Excellence and is a member of the NIH-funded Immune Tolerance Network steering committee. Her research focuses on the use of T regulatory cells to replace conventional immunosuppression in the context of transplantation and autoimmunity. Dr. Levings received her BSc in biology from Simon Fraser University and her Ph.D. in genetics at the University of British Columbia.

About AZTherapiesAZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Our lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease; the ALZT-OP1 Phase 3 COGNITE trial in early Alzheimers disease is fully enrolled, with trial completion expected in late 2020 and results in the first quarter of 2021. Following our lead program, we are advancing candidates for the treatment of amyotrophic lateral sclerosis (ALS), post-ischemic stroke cognitive impairment, and are pursuing an innovative CAR-Treg program that could have broad application across a spectrum of neurodegenerative diseases. AZTherapies is a private company headquartered in Boston, Massachusetts. To learn more, please visit http://www.aztherapies.com.

Media Contact:Jennifer LaVinjlavin@aztherapies.com

Investor Contact:Brian BartlettChief Financial & Accounting Officerbrian.bartlett@aztherapies.com

Here is the original post:
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board -...

FDA Approves TMS Therapy to Treat OCD – MD Magazine

MagVenture TMS Therapy can be used as adjunctive therapy to other OCD treatments.

The US Food and Drug Administration (FDA) has approved transcranial magnetic stimulation (TMS Therapy) for adjunct treatment in adult patients with obsessive-compulsive disorder.

TMS had previously been granted approval to MagVenture for the treatment of major depressive disorder in patients who failed to experience adequate improvement from use of antidepressant medication.The company was the first to receive FDA clearance for the 3-minute Express TMSthe shortest TMS treatment now available.

Now, the out-patient procedure can be used as adjunctive to other OCD treatments that might involve pharmaceutical and behavioral therapy. Using magnetic pulses to stimulate specific areas in the brain, TMS targets its networks and deeper-lying structures that are known to be particularly affected by OCD.

The therapy was not associated with any systemic side effects.

OCD, a mental disorder characterized by obsessions and compulsions, can cause severe disruptions in ones daily life and routines and can lead to further distress and functional impairment. Although there are currently several pharmaceutical and psychological intervention options that are available for these patients, some experience limited improvement and mitigation of symptoms. Thus, the need for greater therapeutic options becomes increasingly necessary.

We have worked closely with brain researchers for well over 25 years, providing numerous TMS solutions to help advance the field of neuroscience both basic and applied, said Kerry Rome, VP of Sales for MagVenture, in a statement. Expanding the treatment options to include other indications than major depressive disorder, such as OCD, is one more important step towards helping more adult patients improve their mental health

Read the original post:
FDA Approves TMS Therapy to Treat OCD - MD Magazine

The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer’s-related abnormalities – PRNewswire

"Darmiyan's AI, machine learning algorithm using unique MRI microscopic voxel analysis with macroscopic input has generated a very sensitive and specific five year prognosis for patients presenting with amnestic MCI," noted Jamshid Ghajar, MD, PhD, FACS, Moghadam Family Director of Stanford Medicine Brain Performance Center. "This technology has high test-retest reliability and can be applied to any clinical grade MRI which is a very useful clinical tool to assist doctors advising patients with early memory complaints."

"Darmiyan's vision excited me because it offers a biologically-based, objective, and sensitive method for detecting changes in the brain that may first show up as subtle changes in memory and cognition and later, as neurodegenerative disease progresses, lead to more serious cognitive and functional deficits. The promise of a new tool that can give patients and their doctors a head start in planning for and possibly even heading off the advance of dementia is exactly what is needed right now, as the aging population grows larger. With the successful conclusion of this project, Darmiyan moves a step closer to delivering on this promise," said Bradley Buchsbaum, PhD, Cognitive Neuroscience Associate Professor at University of Toronto, Senior Scientist at Baycrest Institute & Rotman Research Institute, and the Principal Investigator of the Canadian arm of Darmiyan's validation project.

Validating BrainSeeon Both Clinical-grade and Research-grade Data

The current study showed that BrainSee performs with as high accuracy on clinical-grade data (from patients who present to clinics and hospitals) as it had previously performed on research-grade data (from patients who volunteer for research or clinical trials). This makes BrainSee the first cutting-edge solution that can be easily integrated in any community clinical setting around the world, not just the high-end academic institutions.

A blind retrospective analysis was previously conducted on 411 amnestic mild cognitive impairment (aMCI) patients with research-grade input data (MRI: 3D T1, T2, DTI; plus MMSE & CDR) reporting 90+% performance accuracy. In the current third-party validation study, external investigators blind-tested BrainSee on 107 new patients with clinical-grade input data (routine clinical T1, T2, DWI; plus MMSE & estimated CDR from clinician notes).

While all 107 patients held the same clinical diagnosis label of aMCI, BrainSee visualized and quantified microstructural differences that existed in each patient's brain, and predicted if they would convert to Alzheimer's dementia within 5 years (converter) or stay stable/ improve (non-converter). Investigators compared BrainSee's predictions against the actual clinical diagnosis five years later. The overall predictive accuracy of BrainSee was reported as 91% (Sensitivity 90%, Specificity 92%)."Such an accurate and non-invasive prognostic tool is non-existent in the market today," noted the US investigators.

The current study also included a separate analysis for evaluating BrainSee's test-retest reliability on 84 additional aMCI patients who were recruited to get two brain MRI scans on the same day: one clinical-grade and one research-grade. The test-retest reliability (consistency) of BrainSee was reported very high, with a correlation coefficient of 99.5%.

With this external validation data, the total number of aMCI patients tested by BrainSee has reached 602.

Novel Technological Advantages

"While reading brain PET scans at Stanford & NYU hospitals as a radiologist, I imagined the day when we could help clinicians visualize and evaluate brain health more comprehensively and objectively while posing less discomfort to patients. That day has come now and Darmiyan's BrainSee technology can finally bring clarity to the field of Alzheimer's through visualizing brain tissue microstructure for doctors. Darmiyan's Virtual Microscope technology unlocks the enormous informative potential of the currently underutilized brain MRI scans," said Darmiyan's Chief Medical and Technology Officer, Kaveh Vejdani, MD. "The huge advantage of MRI modality over PET is that it is safer (no radiation exposure), faster, more cost-efficient, non-invasive (does not require radiotracer injection), and much more widely available throughout the world."

According to Dr. Michael G. Harrington, FRCP, Scientific Director of Neuroscience, HMRI, "Objective measures such as Darmiyan's BrainSee that can predict cognitive decline are strongly needed to recognize and monitor potential therapies."

Meeting Today's Clinical Needs

Alexandra Papaioannou, MD, Executive Director, and George Ioannidis, PhD, Associate Scientific Director of GERAS Centre at HHS (both Professors of Medicine at McMaster University) noted that Darmiyan's non-invasive technology "could result in an important development in the Alzheimer's field" as it has "performed well in predicting disease progression" and can "improve clinicians' workflow and how patients are monitored."

David J. Mikulis, MD, Professor and Director of the JDMI (Joint Department of Medical Imaging) Functional Neuroimaging Research Lab, UHN, noted: "I was impressed by the potential of this breakthrough technology. All study investigators are optimistic that Darmiyan's solution will be successful providing a much needed predictor of disease progression. It may therefore fill a significant diagnostic gap highly valued by patients, clinicians, and clinical researchers."

"With the great help of our clinical trials sites in the US and Canada, we demonstrated that BrainSee can well integrate in the clinical workflow without imposing any limitations, such as specific MRI protocol, in the process of monitoring MCI patients," said Darmiyan's CEO Padideh Kamali-Zare, PhD. "These data support our vision to make BrainSee readily accessible for all people worldwide addressing the dire need for accurate diagnosis of Alzheimer's disease and prognosis of mild cognitive impairment in clinics and clinical trials. Localizing and quantifying early signs of brain cell distortion, in a way that is agnostic to specific protein-based biomarkers such as amyloid or tau, is key to understanding the disease pathology early on in its process and providing personalized treatments suitable for each Alzheimer's patient in the future."

About Darmiyan, Inc.

Darmiyan(based in San Francisco, CA) was incorporated in September 2016 and backed by Y-Combinator (YC) in Summer 2017. The Company has won numerous awards and recognitions including the TEDMED Hive Innovator in 2018 and CABHI Innovation Award in 2019. Darmiyan's most recent funding in 2020 was led by the global pharma giant Eisai with participation of YC and IT-Farm.

SOURCE Darmiyan

Home

More:
The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer's-related abnormalities - PRNewswire

Revisiting the industrial revolution in scientific lasers – Laser Focus World

ALLAN ASHMEAD, STEVE BUTCHER, and MARCO ARRIGONI

Experience from decades of industrial laser applications, along with vertical integration leading to better components and materials, have enabled laser manufacturers to build scientific lasers with industrial reliability. At Coherent (Santa Clara, CA), investment in an immersive reliability concept called HALT/HASS long used in other reliability-critical industries has assisted in achieving this goal (HALT stands for highly accelerated life testing and HASS stands for highly accelerated stress screening). For example, in a 2014 Laser Focus Worldarticle entitled Ultrafast scientific lasers undergo an industrial revolution, Coherent noted that a one-box femtosecond oscillator was delivering levels of reliability that opened the path towards significant advances in data productivity.

Six years is a long time in a dynamic field like ultrafast lasers, so now seems like a reasonable time to assess if and how this industrial revolution has progressed, and more importantly, how it has impacted real scientific studies. This second article on the topic focuses on the more complex and challenging domain of femtosecond amplifiers.

For many years, titanium sapphire (Ti:sapphire) was the gain material of choice in virtually every ultrafast amplifier and oscillator. Today, however, ytterbium (Yb)-doped crystals or fibers are well-established alternatives to Ti:sapphire and complement its performance capabilities. Ytterbium has the advantages of being directly and efficiently pumped by laser diodes, resulting in a smaller quantum defect than Ti:sapphire. As a result, Yb lends itself to more-compact platforms.

From an applications viewpoint, the important differences are power, pulse energy, and repetition rates. Ti:sapphire amplifiers are unmatched in their ability to deliver high pulse energy. Coupled with the short pulses (less than 35 fs) of turnkey Ti:sapphire amplifiers, this translates into peak powers approaching the terawatt level. These amplifiers are therefore favored for applications requiring high fluence such as strong-field physics and high harmonic generation (HHG) for extreme ultraviolet (EUV) or attosecond-pulse generation.

The optimum performance of one-box Ti:sapphire amplifiers is at low repetition rates: 110 kHz. Ytterbium amplifiers, on the other hand, have lower pulse energy, but deliver much-higher average power (tens of watts) with extremely flexible repetition rates up to the megahertz regime. As a result, Yb amplifiers are optimum for applications requiring fast data collection with modest energy requirement (such as imaging and solid-state spectroscopy) or where high average power is critical (such as materials processing). Moreover, as a newer material, Yb amplifiers have more room for performance improvements.

This article will examine four applications, three scientific and one industrial, that highlight the impact of the industrial revolution on day-to-day performance, reliability, and productivityeither in terms of data or process throughput.

Ferroelectric materials and films can support a permanent electric dipole (meaning electrically polarized), which is why they are already widely used in electronic and photonic devices. However, more-detailed information is needed on films as thin as a few unit cells, as these could support higher density electronics and also offer the potential of custom (atomic-scale) novel ferroelectric heterostructures. A group led by Dr. Morgan Trassin and Prof. Manfred Fiebig at ETH Zurich (Switzerland) has been conducting the first in situ measurements of film polarity during the actual growth process performed by pulsed laser deposition with an excimer laser (Coherent LPX 220).

In any material where there is a break in symmetry and long-range order, irradiating with intense laser light can result in some second-harmonic generation (SHG). This effect has already been used in the past as a diagnostic with thicker ferroelectric samples. However, no one had previously demonstrated in situ harmonic generation (ISHG) during the film growth process.

SHG is highly sensitive to polarization, says Trassin. So, we reasoned that we could use the polarization dependence of the SHG signal to map the alignment of domains in a ferroelectric film. And, more importantly, we wanted to investigate the potential of ISHG to follow the polarization (or depolarization) of ultrathin films during the epitaxial deposition process. The light source for their SHG setup is a Ti:sapphire one-box amplifier (Coherent Astrella) that pumps a tunable optical parametric amplifier (OPA).

The technique has proved successful and has been capable of measuring ferroelectric polarization properties, as films are grown from zero to just a few unit cells in thickness. Based on this success, the Trassin group has applied this technique to examine the local polarization orientation, as the layers are incorporated into heterostructure model devices.

What is the impact of industrial reliability? The stability of this amplifier to changes in ambient temperature is particularly important to our work, says Trassin. We grow these films in a deposition chamber with internal temperatures up to 950C, so the temperature of our lab unavoidably varies considerably during the day (see Fig. 1). But critical amplifier output (pointing and power) parameters are thankfully unaffected.

2D spectroscopy involves measuring an optical signal as a function of pulses with two different optical frequencies and provides a wealth of data that would be impossible to obtain by any other method. The signal can be based on various different processes, including absorption, Raman, and sum/difference frequency generation. The data can be presented as two-dimensional contour graphs plotted against two frequencies, but are usually recorded as time-domain data and then Fourier-transformed in the frequency space. To ensure coherence, the three (or four) different femtosecond pulses required for these measurements are generated from a single source using a pulse shaper in what is essentially a four-wave mixing effect in the sample. The very wide spectral bandwidth of the short Ti:sapphire pulses critically enables a wide frequency range to be covered in a single set of data.

A group led by Professor Wei Xiong at the University of California, San Diego has recently used 2D spectroscopy to investigate a heterogeneous CO2 reduction catalyst, Re(diCN-bpy)(CO)3Cl, bound as a monolayer on gold surfaces. The researchers have performed experiments based on sum-frequency generation (SFG), a technique originally developed by Xiong as a graduate student in the lab of Martin Zanni. SFG vibrational signals are only generated at surfaces and phase interfaces. So, comparison with 2D spectra of the unbound catalyst (that is, in solution) enabled the Xiong group to reveal how the catalyst is bound to gold (see Fig. 2) and how its bond structure is impacted by this.FIGURE 2. Orientations of a catalyst on a gold surface determined from HD 2D SFG data and data from reflection-mode infrared spectroscopy is simulated using density functional theory (DFT). Orientation a is preferred. Blue lines represent directions of the vibrational modes.(Courtesy of Wei Xiong)

Xiong cites the operational simplicity of their one-box industrialized amplifier (Coherent Astrella) as a key benefit in these inherently challenging experiments. Just as important is the long-term stability: some of their time-resolved experiments (i.e., 3DSFG) require data runs in excess of 40 hours, during which the amplifier output must remain perfectly stable.

Two-photon microscopy and related techniques represent a major market segment for one-box oscillators, particularly in neuroscience, and now one-box Yb amplifiers are starting to enable new neuroscience applications. The main applications here are three-photon (3P) microscopy, photostimulation of groups of neurons, and photoablation of select neurons. These all require one or more of the main Yb amplifier advantages: long output wavelength, high repetition rate, and high average power. For example, high power is needed for two-photon photostimulation of hundreds of neurons using optogenetic expression. The power requirement stems from the large number of cells to be stimulated simultaneously, as well as system losses in spatial light modulators (SLMs).

Three-photon microscopy is a relatively new technique that depends on the simultaneous absorption of three photons, a low-probability event that therefore requires the high photon flux from an amplifier rather than an ultrafast oscillator. As a scanning-imaging application, high repetition rate is also necessary to acquire many pixels. Here, a Yb amplifier is usually combined with a tunable OPA to deliver high power in the 1.3 and 1.7 m wavelength windows that yield deeper penetration into brain and other scattering tissues.

Professor Raluca Niesner at the German Rheumatism Research Center (DFRZ; Berlin, Germany) recently used a Yb amplifier (Coherent Monaco) together with an OPA (Coherent Opera-F) to perform 3P imaging inside lymph nodes. These are densely packed with cells, which causes scattering issues for two-photon microscopy.

One of the targets of my research group is improved understanding of the rogue inflammatory response that results in rheumatoid arthritis in particular, and in chronic inflammatory diseases in general, says Niesner. Preliminary studies of mouse-limb lymph nodes by Dr. Rakhymzhan in Niesners laboratory indicate that 3P excitation can deliver a dramatic increase in deep imaging capabilities, specifically a greater-than 2X increase in maximum imaging depth for 3P vs. 2P under identical conditions. Figure 3 shows typical images.FIGURE 3. Murine lymph-node z stack images, where z = 300 m, are obtained using a Coherent Monaco Opera-F combination tuned to a wavelength of 1630 nm and a LaVision Trim Scope microscope. The red image is due to 3P excitation of tdTomato (a fluorescent protein) detected at 595 (20) nm (a), the white image is due to SHG signals from collagen fibers detected at 810 (45) nm (b), and the green signal originates from THG of lipid bilayers, lipids, or other anisotropic structures and was detected at 525 (25) nm (c). The composite image combines the tdTomato and SHG signals (d).

Surely nothing illustrates the success of the industrialization of scientific ultrafast lasers more than the use of the same laser in both scientific and industrial applications. Bringing the story full circle, a brief look is taken at an industrial application that illustrates both the flexibility of Yb amplifiers and the broad benefits of the industrial revolution approach to scientific and commercial applications.

Lasers with ultrashort pulse durations have long been used in micromachining (cutting, drilling, scribing, and so on) because the short pulse duration minimizes the heat-affected zone (HAZ)the extent of surrounding material that exhibits undesirable thermal damage such as melting/resolidification or microcracking. The HAZ is minimized when the pulse duration is short compared to the thermal diffusion time in the target material, so that most of the extra heat associated with the cutting or drilling process is carried away in the ejected debris before it has time to spread into the surrounding material.

Until recently, ultrashort-pulse (USP) industrial lasers have been mostly confined to the picosecond domain, limited by the bandwidth of the neodymium (Nd)-doped gain medium. However, for some applications, even the small HAZ from picosecond lasers was problematic, indicating a need for even shorter pulse durations. Unfortunately, femtosecond amplifiers based on Ti:sapphire do not have the requisite combination of high repetition rates and high average power. The advent of Yb femtosecond amplifiers with output powers up to 60 W has thus completely changed this situation. One of the first applications to benefit has been medical device fabrication.

A standout example can be found at Motion Dynamics (Fruitport, MI), a manufacturer of difficult subassemblies for the medical market such as steerable catheter products for neurovascular interventions. They use a four-axis cutting machine (Coherent StarCut Tube) equipped with a Monaco femtosecond amplifier rated at 60 W (see Fig. 4). Chris Witham, President of Motion Dynamics says, Our products require cutting and drilling a range of different metals, including gold, where surface roughness and edge quality are critical qualities. The femtosecond laser enables us to fabricate these components in a single step, typically with no polishing or other postprocessing required.FIGURE 4. An example of a wire/spring subassembly cut with a Yb femtosecond amplifier (Coherent Monaco).(Courtesy of Motion Dynamics)

The success of the industrial revolution in ultrafast science has been clearly demonstrated in these, and many other, representative applications that are critically enabled by the reliability and stability resulting from this design and manufacturing approach.

Allan Ashmead is VP of the Research Laser Systems business unit, Steve Butcher is director of marketing for the Scientific Market, and Marco Arrigoni is director of marketing for the Advanced Systems business unit, all at Coherent, Santa Clara, CA; e-mail: allan.ashmead@coherent.com;coherent.com.

Follow this link:
Revisiting the industrial revolution in scientific lasers - Laser Focus World

Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neurosciences influence expands – Vanderbilt University News

Science Photo Library

The ancient Egyptians were the first to mention the brain in writingpreserved on a 2,700-year-old papyrus that details the symptoms of head injuriesbut the importance of the organ escaped them. They believed it was the heart, not the head, that controlled human thought and emotion.

Today our knowledge of the brain has far eclipsed what our forebears knew only a few generations ago, never mind 27 centuries. The burgeoning field of neuroscience has led to an almost unprecedented burst of scientific research, reshaping disciplines from biochemistry and personalized medicine to law, psychology and the arts. Meanwhile, newer imaging technologies, like functional magnetic resonance imaging (fMRI), have offered revolutionary ways to view brain activity in real time.

As a result of these and other breakthroughs, neuroscience has permeated our lives as never before. Yet, as researchers learn more about the brain, the more its mysteries grow in ways that dont lend themselves easily to a single discipline. Scientists have been unable to disentangle, for example, genetics and anatomy from human experience and emotion.

What is required instead is a closely collaborative, multidisciplinary approach to understanding the brain. For more than 20 years, Vanderbilt has done just that, leveraging its culture of collaboration to emerge as a leader in neuroscience research and education. Now, as our knowledge of neuro-everything continues to growaided by emerging technologies like artificial intelligence and data sciencethe university has reaffirmed its commitment to this important space.

Vanderbilt is on the leading edge of neuroscience discovery in research, education and training, says Provost and Vice Chancellor for Academic Affairs Susan R. Wente. You can see it in the breadth of our neuroscientists work, from their innovative use of scanning technology to better understand the brains many functions, to the advances theyve made in pharmacology and biochemistry as they pursue treatments for some of the worlds most vexing neurological disorders.

More important, though, you see it in how these scientists work together across their diverse fields, lending expertise and support to each others efforts, as they further our knowledge of the brain. Vanderbilts success in neuroscience ultimately depends on this teamwork.

At the center of this work is the Vanderbilt Brain Institute, a trans-institutional entity that oversees and facilitates neuroscience-related endeavors across the university and in partnership with Vanderbilt University Medical Center. The VBI recently marked its 20th anniversary, a span that has seen the institutes wide-ranging missionsincluding administering the universitys Neuroscience Graduate Program, as well as postdoctoral training and community outreachsteadily coalesce under a single umbrella.

Of those 20 years, the past two in particular have been among the most transformative for the VBI, as Vanderbilt has allocated new resources toward its continued expansion, including a reimagined physical home on campus. The university also has raised the institutes visibility by bringing in Lisa Monteggia, an esteemed researcher and educator from UT Southwestern Medical Center in Dallas, to lead it.

Hired in September 2018 as the VBIs Barlow Family Director following a nationwide search, Monteggia has begun implementing a forward-looking plan for the institute, making strategic decisions and investments that not only expand and enhance Vanderbilts neuroscience community and its collaborative spaces on campus but also harness the creative, cross-disciplinary synergy that naturally results from those efforts.

The idea is to take advantage of our strengths, including the incredible collegiality we have as a smaller university, as we continue to grow and build, says Monteggia, who is also a professor of pharmacology. Were hiring new faculty and also exploring different areas of collaboration, like connecting the arts with psychiatry, for example, or the biological sciences with education and engineering. Its really about building bridges that further our understanding of the brain.

Vanderbilts roots in neuroscience stretch back several decades before the launch of the VBI. For example, in the 1950s and 60s, developmental psychologist Susan Grays pioneering work helped George Peabody College for Teachers develop a national reputation for research on intellectual and developmental disabilities, leading to the launch in 1965 of what is today known as the Vanderbilt Kennedy Center for Research on Human Development. The VKC works to improve the lives of people with intellectual and developmental disabilities through research, education and advocacy.

By the 1970s there would be other key faculty additions, including the late psychology professor Oakley Ray, who introduced the academic focus of neuropharmacology, and Jon Kaas, the Gertrude Conaway Vanderbilt Distinguished Professor of Social and Natural Sciences.

Since his arrival at Vanderbilt in 1973, Kaas has seen the neuroscience landscape at the university grow significantly, thanks in part to his own numerous contributions to the field, including illuminating how sensory information is distributed and integrated in the brain. But Kaas is also quick to note the impact of other faculty who have brought neuroscience to the forefront at the university.

Among them was the late Vivien Casagrande, professor of cell and developmental biology, psychology, and ophthalmology and visual sciences, whom Kaas helped convince to come to Vanderbilt. Arriving on campus in 1975, she spent the next several decades expanding our knowledge of how the visual thalamus and cortex interact to construct our perceptual world.

Says Kaas, She was really the first faculty member trained as a neuroscientist to be hired at Vanderbilt.

Casagrande and Kaas were founding members of the Vanderbilt Vision Research Center (VVRC), launched in 1989 to enhance research and training in visual neuroscience in the Department of Psychology, Department of Ophthalmology and Visual Sciences, and others at the Medical Center. The concentration in vision science attracted other key faculty, including Randolph Blake, MA69, PhD72, Centennial Professor of Psychology and professor of ophthalmology and visual science, in 1988, and Jeffrey Schall, E. Bronson Ingram Professor of Neuroscience and professor of psychology and ophthalmology and visual sciences, in 1989.

Like Kaas, both are among the two dozen or so neuroscientists at Vanderbilt who have been elected fellows of the American Association for the Advancement of Science. Blake studies human visual perception, including binocular vision, motion perception and perceptual organization, while Schall investigates the neural and computational mechanisms of decision making.

Kaas also points to the hiring in 1991 of Ford Ebner, professor of psychology, emeritus, who has helped further our understanding of the brains plasticity (i.e., its ability to be molded and shaped by experiences), and his wife, Leslie Smith, principal senior lecturer of psychology. Vanderbilts first neuroscience Ph.D., in fact, was awarded to one of Ebners students. Kaas credits Smith, who previously had taught at Brown University, for elevating neuroscience education at Vanderbilt, particularly on the undergraduate side.

Leslie introduced the idea of a neuroscience major, and that really set things in motion, says Kaas of what is today the Interdisciplinary Program in Neuroscience for Undergraduates. The undergraduate program has fed into our graduate program and everything else that has come since.

Started in 1997, the undergraduate program, which is now administered by the VBI, is today the third largest major in the College of Arts and Science, with 355 students. Those who major in neuroscience typically go on to some of the countrys most competitive medical schools or graduate programs in neuroscience, biology or psychology.

Meanwhile, as the undergraduate program was getting off the ground, Elaine Sanders-Bush, PhD67, professor of pharmacology, emerita, led the launch of the Neuroscience Graduate Program and would go on to serve as its director until 2008. During that decade the program grew to more than 60 graduate students. Since then, it has evolved into the largest graduate program on campus with 109 training faculty and 82 current students.

The development of undergraduate and graduate programs in neuroscience was paralleled by the establishment of institutional research centers. The Center for Molecular Neuroscience, founded under direction of Randy Blakely in the School of Medicine, organized resources and motivated faculty hiring to investigate the cells and molecules of the brain. The complementary Center for Integrative and Cognitive Neuroscience, launched in 2000 under the direction of Jeffrey Schall, organized resources and motivated faculty hiring to investigate the circuits and functions of the brain.

The Vanderbilt Brain Institute was established to administer the graduate program and facilitate synergy of these centers with the VKC, VVRC and the involved departments. Sanders-Bush, whose research has contributed to our understanding of serotonin and its receptors, also served as the VBIs first director.

Coinciding with the launch of the VBI in 1999 were a couple of new faculty additionsIsabel Gauthier, David K. Wilson Professor of Psychology, and Ren Marois, professor and chair of the Department of Psychology and professor of radiology and radiological scienceswho would prove to have an important impact at Vanderbilt. Both had earned their Ph.D.s at Yale University andalong with Randolph Blake and Ford Ebnerwere early promoters of fMRI, Gauthier using it to explore visual object recognition and Marois to study the neural bases of attention and information processing.

Their move to Vanderbilt would help prompt their Yale mentor John Gore to follow them, bringing more than a dozen colleagues to establish the Vanderbilt University Institute of Imaging Science in 2002. Gore, the University Professor of Radiology and Radiological Sciences and holder of the Hertha Ramsey Cress Chair in Medicine, is known internationally for his pioneering work in biomedical imaging techniques.

During the past two decades, the university has become a magnet for other prominent neuroscientists, with a number of influential centers focused on brain research taking root, including the Warren Center for Neuroscience Drug Discovery and the Center for Cognitive Medicine.

As the VBI continued to evolve into a more cohesive framework, it got a champion in the form of Mark Wallace, an expert on multisensory processing who became director in 2008. Currently the dean of Vanderbilts Graduate School and holder of the Louise B. McGavock Chair, Wallace led the VBI to national prominence, spurring research while also bolstering its education initiatives, including helping launch the countrys first Ph.D. program in educational neuroscience at Peabody College in 2012.

Wallaces decision to step down from the VBIs directorship and become dean in 2016 provided an opportunity for Vanderbilt to refocus its approach to neuroscience. To aid in the search for Wallaces successor, David Barlow, the chairman and CEO of Psy Therapeutics, a Boston-based startup developing treatments for anxiety, depression and dementia, provided the gift to endow the Barlow Family Directorship, ensuring that the VBI would be able to recruit the best talent to that position in both the near and long term. (Among the members of Psy Therapeutics scientific advisory board is Dr. Sachin Patel, the James G. Blakemore Professor of Psychiatry, who studies cannabinoid neurobiology at Vanderbilt.)

While the VBI already had a solid foundation, there was a clear opportunity to grow the mission and expand, says Barlow, who got involved with Vanderbilt, including service on the Technology Transfer Advisory Committee, after his daughter Kelly Barlow, BA12, was a student. It was exciting to think about leveraging the ethos on campus and turning the institute into a hub that further facilitates interdisciplinary collaboration.

The VBI has a huge future ahead of it under Lisas leadership.

Coupled with the endowed directorship was a decision to move the VBI under the Office of the Provost. Aside from raising the institutes stature and visibility on campus, the move afforded a more direct line of communication with Wente, herself a pathbreaking scientist who was instrumental in convincing Monteggia to join Vanderbilts faculty.

Its unusual to have a provost with such a strong scientific background. She understands the importance of investing in the best science and has been incredibly supportive, Monteggia says. As a colleague reminded me before I took the job, there are very few opportunities like this that come along in any given professional career. The opportunity to lead and serve the VBI was simply too great to pass up.

Monteggias research focuses primarily on two areas. One is antidepressants and how they work, with the particular goal of developing more effective treatments for depressed individuals who have exhibited resistance to conventional drugs and are therefore more prone to suicide. The other area is the underlying causes of Rett syndrome, an autism spectrum disorder. While antidepressants and Rett syndrome may seem like two very distinct paths of inquiry, they overlap in one critical sense.

Certain neurodegenerative disorders, like Alzheimers, are characterized by loss of particular cells, Monteggia says. But there are other disorders like depression and autism that display no gross morphological anatomical changes in the brain. That suggests they are caused instead by functional changes at the level of how the neurons communicate. So we work backwards and look at a number of genes that are linked to these processes.

Finding common ground to explore these and other neuroscience questions is a key part of Monteggias vision for the VBI, and for her that begins quite literally with the physical location itself. Upon accepting the directorship, she worked with Wente to establish a better-defined home for the institute on the seventh and eighth floors of Medical Research Building III. The space now includes expanded offices and conference rooms, additional seating lounges, and a refurbished balcony area to host visiting luminaries in the field and other gatheringsall designed with the aim of fostering collaboration.

Were currently 109 faculty members split across 24 different departments, Monteggia says of the VBI. And neuroscience is also the largest graduate program on campus. So the idea is to have a place for them all to come. Its about bringing people together to talk about ideas, discuss projects, and just get to know each other.

As expansive as the VBI already is, Monteggia wants to continue growing the institute by working with deans on campus, particularly those at the College of Arts and Science, Peabody College, the School of Engineering, and the School of Medicines Basic Sciences, to make strategic faculty hires. And as part of that process and the VBIs other initiatives, she is ever mindful of the role that diversity and inclusion should play in that growth.

Im a firm believer that the more diversity we have, the better well be able to approach a problem and see it from different angles, she says.

Monteggia also recognizes that the VBIs role doesnt stop at the edge of campus. Its work can and should reverberate well beyond the classrooms and labs and into the wider community of Middle Tennessee, she says. This includes, among other things, having Vanderbilt students speak at local schools on neuroscience-related topics, collaborating with the Osher Lifelong Learning Institute on programming related to the aging brain, and organizing free public events and activities for Brain Awareness Month each March.

Ultimately, the VBIs work is part of a long continuum of efforts, now many centuries old, to demystify the brain and unwind its tangled secrets for the greater benefit of society. This endeavor has pushed our knowledge of neuroscience further than many ever could have predicted only a few generations ago, but there remains so much more we do not understand about the brain. And if the past is any indication, the more deeply we peer inside its folds, the more questions there likely will be.

As were going about this transformation, theres always an eye towards the future. I do have a vision for where were going, but Im trying to do it in a way that brings the most people together as possible, Monteggia says. Thats the only way well be able to answer these big questions facing science and society as a whole.

Seth Robertson is executive editor of Vanderbilt Magazine.

Read more:
Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neurosciences influence expands - Vanderbilt University News

What happens in the brain when we sleep? – Medical News Today

What occurs in the brain when we are deep in slumber? What are the different stages of sleep and what role do they play in learning and memory formation? What about in anxiety and pain? Do neurons and neurotransmitters also play a role? These are the questions we will tackle in this Special Feature, using the latest evidence available.

Scientists generally agree that there are four stages of sleep that we cycle through several times each night. The first three form the so-called non-rapid eye movement (REM) sleep and the fourth one is REM sleep where dreams occur.

In the first non-REM stage, the body and brain transition from wakefulness to sleep. The brain changes its electrical oscillations from the active, wakefulness pattern of brainwaves into a slower rhythm.

Muscle tone throughout the body relaxes. This is the phase during which our bodies may twitch as we enter slumber.

The second non-REM stage involves a drop in the bodys temperature, the heartbeat and breathing become slower, and the brainwaves slow down further. Short bursts of electrical activity in the brain may still characterize this stage of sleep.

The third stage of non-REM sleep is the deep sleep stage, which our bodies need to wake up feeling refreshed and restored. In this stage, heart rate, breathing, and brain activity all drop to their lowest point.

The REM, dream-filled light-sleep stage is the fourth and last one. According to the National Institute of Neurological Disorders and Stroke (NINDS), REM occurs about 90 mins after falling asleep.

REM sleeps lasts roughly 10 minutes the first time, increasing with each REM cycle. Rapid eye movement is so-called because the eyes quite literally move rapidly behind closed eyelids.

During REM, breathing becomes more rapid and irregular, heart rate and blood pressure increase to near waking levels. An interesting fact about REM sleep is that people experience less and less of it as they grow older.

One of the two main things that control sleep is the ensemble of physical, mental, and behavioral changes that follow a daily cycle called circadian rhythms. The term circadian comes from the Latin circa, meaning around and dies, meaning day.

Circadian rhythms respond to the light-darkness cycle and are genetically predetermined, at least in part, and dictated by so-called biological clocks proteins that interact within cells in every tissue and organ in the human body.

The suprachiasmatic nucleus, a structure in the brain formed by a group of about 20,000 neurons, or nerve cells, coordinates all the biological clocks.

Secondly, the sleep-wake homeostasis also tracks a persons need for sleep and dictates when they get sleepy. The so-called homeostatic sleep drive increases with the time that a person spends being awake. Its visible effects on brain activity and connectivity between neurons have been well documented.

Another area that has been the focus of much research is the relationship between sleep and learning or memory formation. Scientists know for sure that sleep is crucial for learning but which stage of sleep is more important?

Does learning occur in the light REM sleep stage or the deep, non-REM phase of sleep? How do neurons in different brain areas coordinate across sleep stages to facilitate learning and memory consolidation?

Two studies that Medical News Today reported on help to shed light on these questions.

In the first study, the experimenters tampered with the study participants deep, non-REM sleep stage after asking them to learn a new set of movements. The scientists monitored the participants brain activity their motor cortex, specifically throughout the study.

The team led by Switzerland-based scientists found that a restless deep sleep resulted in a visibly reduced learning efficiency. The researchers explained that their results hinged on the brains synapses and their roles in learning.

Synapses are microscopic connections between neurons that, together with brain chemicals, or neurotransmitters, facilitate the passing of electrical impulses from one neuron to another. During the day, synapses switch on in response to the stimuli that the brain receives from the environment.

But during sleep, the activity of these synapses goes back to normal. Without this restorative period, they stay excited at their peak activity for too long.

This interferes with the brains neuroplasticity that is, its ability to re-wire itself and create new connections between neurons. Neuroplasticity enables the brain to pick up new skills, change and adapt to its environment stimuli, and ultimately learn new things.

Nicole Wenderoth, a professor in the Department of Health Sciences and Technology at the ETH Zurich, and co-lead author explains what occurred in their new study.

In the strongly excited region of the brain, learning efficiency was saturated and could no longer be changed, which inhibited the learning of motor skills.

To the authors knowledge, this was the first study that showed a causal relationship between the deep phase of sleep and learning efficiency. We have developed a method that lets us reduce the sleep depth in a certain part of the brain and therefore prove the causal connection between deep sleep and learning efficiency, says study co-author Prof. Reto Huber.

The second study that MNT reported on looked at different sleep stages. However, this research showed that sleep does not just enable the brain to learn new things but also unlearn.

The original 2017 study involved an auditory learning task. The researchers played sound sequences while the participants were asleep and awake.

They monitored the volunteers brain electrical activity using an electroencephalogram (EEG).

The EEGs also captured sleep spindles that occurred when the sleeping brain learned new sounds. Sleep spindles are spikes in oscillatory brain activity that previous research has linked with learning and memory consolidation.

After each sleep session, the experimenters asked the participants to re-listen to the sound sequences and recognize them. They assessed their learning performance through tests.

Using the EEG readings, the scientists examined three sleep phases: REM sleep, light non-REM sleep, and deep non-REM sleep.

When exposed to the sounds during REM sleep or during light non-REM sleep, the participants were better at recognizing them when awake. But, when exposed to the new sounds during deep non-REM sleep, they had a harder time recognizing the sound sequence during wakefulness.

Also, while EEG markers of learning were readily observed in light [non-REM] sleep, they were markedly absent in deep [non-REM] sleep, report the scientists.

Furthermore, and importantly, not only was it hard for the participants to recognize the sounds that the researchers had played to them in their deep non-REM sleep, but they also found it more difficult to (re)learn these sounds, compared with entirely new sounds.

The findings suggest that deep non-REM sleep is not so much to learn new things as it is to suppress information.

[The] biggest surprise came from the brains ability to unlearn. Thus, it seems that during sleep, we can either form new memories, learn, or do the reverse: suppress memories and unlearn.

Thomas Andrillon, study first author

They also add to the evidence that deep sleep helps maintain neuroplasticity. Specifically, light non-REM sleep (stage 2) may help excite synapses, while deep non-REM sleep may help them relax, or downscale.

Such a contrast between light [non-REM] and deep [non-REM] sleep is consistent with a qualitative distinction between these two sleep stages in relation to neural plasticity, write the authors. According to this view, light [non-REM] sleep favors synaptic potentiation, while deep [non-REM] sleep favors synaptic downscaling.

We do not suggest any functional role for the suppressive effect of information presented during sleep, they add. Rather, it seems an inevitable byproduct of the synaptic downscaling needed for homeostatic purposes.

In other words, deep sleep may help us unlearn or forget because forgetting is a natural byproduct of preserving neuroplasticity; forgetting is a byproduct of our ability to learn.

Andrillon and colleagues also explained that their findings are significant because they help unify two previously contradictory schools of thought. One sees sleeps primary function as learning and consolidating new information. The other sees it as discarding useless information so as not to overwhelm the brain.

As scientists gather more and more neuroscientific evidence about how sleep works, it becomes apparent that overall, such divisions and dichotomies are perhaps not the most useful way of looking at sleep or the role sleep has in learning.

For example, a study published only last month shows that REM and non-REM sleep work together to boost learning.

Namely, non-REM sleep boosts the performance of newly acquired skills by restoring flexibility and neuroplasticity, while REM sleep stabilizes these improvements and prevents new learning from erasing them.

The new research started from the same hypothesis that the studies above seem to highlight that sleep must strengthen the synapses and the neuronal connections created during the day (to solidify new knowledge and prevent it from being overwritten by new information). However, it must also downscale, or relax or weaken, the synapses to preserve their flexibility and the brains neuroplasticity.

This study led by Masako Tamaki, from the Department of Cognitive, Linguistic, and Psychological Sciences at Brown University in Providence, RI involved a visual learning task. The researchers assigned one group of participants two different tasks, one before sleep and one after sleep. The other group did not receive any learning tasks.

The scientists used MRI scanners and electrodes that they applied to the participants heads and eyelids. They also used magnetic resonance spectroscopy to measure the two brain chemicals involved in neural plasticity (or flexibility of the synapses) and stabilization.

Tamaki and team found that neuroplasticity increased during non-REM sleep. This had associations with better learning and task performance after sleep.

During REM sleep, the participants neural plasticity dropped, which correlated with the stabilization of what they had learned. The researchers hypothesize that REM sleep helps prevent learning before sleep from being overwritten by subsequent learning.

Unlike non-REM sleep, the researchers only saw the sharp fall in plasticity during REM sleep among the volunteers with a task to learn.

In the researchers words: The [neuroplasticity] increased during NREM [non-REM] sleep irrespective of whether pre-sleep learning occurred, but it was associated with post-sleep performance gains relative to pre-sleep performance. In contrast, the [neuroplasticity] decreased during REM sleep but only after pre-sleep training, and the decrease was associated with stabilization of pre-sleep learning.

These findings indicate that NREM sleep promotes plasticity, leading to performance gains independent of learning, while REM sleep decreases plasticity to stabilize learning in a learning-specific manner.

Masako Tamaki et al.

It is not just synapses that may help or hinder the learning process during sleep but also the neurons themselves. Some researchers have identified specific neurons with key roles in memory formation that help us actively forget dreams.

For instance, research appearing in the journal Science has located some of these neurons in the hippocampus, a brain area crucial for forming memories and learning.

Akihiro Yamanaka, Ph.D., from Nagoya University, Japan, and his colleagues experimented with some of these neurons that produce a melanin-concentrating hormone (MCH) that helps regulate both sleep and appetite.

Yamanaka and team conducted experiments in mice, which showed that the firing of this particular group of [MCH-producing] neurons during REM sleep controls whether the brain remembers new information after a good nights sleep.

Genetically deleting these neurons in mice suggested that these cells help the brain actively forget new, possibly unimportant information. What is more, the findings point to the role that these neurons have in forgetting dreams.

Co-lead author Thomas Kilduff, Ph.D., the director of the Center for Neuroscience at the SRI International research institute in Menlo Park, CA, explains.

Since dreams are thought to primarily occur during REM sleep, the sleep stage when the MCH cells turn on, activation of these cells may prevent the content of a dream from being stored in the hippocampus consequently, the dream is quickly forgotten.

The neuroscience of sleep helps explain how sleep helps us learn and forget. It also sheds light on sleeps pain-relieving and anti-anxiety effects.

For example, a study published last year found that a brain area associated with pain sensitivity (called the somatosensory cortex) is hyperactive in sleep-deprived participants. The findings suggested that not getting enough sleep interferes with the brains pain-processing neural circuits.

Additionally, the same study found that activity in the nucleus accumbens area of the brain had dropped after a sleepless night. The nucleus accumbens releases the neurotransmitter dopamine, which heightens feelings of pleasure and decreases sensations of pain.

Sleep loss not only amplifies the pain-sensing regions in the brain but blocks the natural analgesia centers, too, explains the senior study author Matthew Walker, a professor of neuroscience and psychology at the University of California in Berkeley.

The team also found that the brains insula, which evaluates pain signals and prepares the pain response, was also underactive in sleep-deprived people.

Sleeplessness interferes with this critical neural system that assesses and categorizes the pain signals and allows the bodys natural painkillers to come to the rescue, notes Adam Krause, the studys lead author.

As to the anxiolytic effects of sleep, functional MRI scans and polysomnograms have shown that the medial prefrontal cortex in the brain is key. This region deactivated after a sleepless night in some studies co-led by the same Prof. Walker.

Previous research suggests that the medial prefrontal cortex helps calm anxiety and reduce stress levels. In Prof. Walkers research, other regions associated with processing emotions were hyperactive in sleep-deprived patients.

Without sleep, Prof. Walker explains, its almost as if the brain is too heavy on the emotional accelerator pedal, without enough brake. A sleepless night caused anxiety levels to spike by up to 30% in their study, report the scientists.

Furthermore, the study found that anxiety levels dropped after a full night of sleep and that this decrease was even sharper in participants who spent more time in the deep non-REM stage of sleep.

Deep sleep had restored the brains prefrontal mechanism that regulates our emotions, lowering emotional and physiological reactivity, and preventing the escalation of anxiety.

Eti Ben Simon, study co-author

Link:
What happens in the brain when we sleep? - Medical News Today

WVU Rockefeller Neuroscience Institute expands pioneering Alzheimer’s treatment to wider region of the brain – DOTmed HealthCare Business News

A hospital nurse for 33 years, Nanette Miller would call her husband Frank at the end of each shift to let him know she was coming home. On Dec. 7, 2018, the phone call came with a somber declaration: I cant do this anymore.

Miller had to help on another hospital floor that day. She didnt know how to get back.

Several months later, she was diagnosed with what she and her husband had feared early onset Alzheimers disease.

Ad StatisticsTimes Displayed: 1079778Times Visited: 9495

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Using focused ultrasound, Dr. Ali Rezai, executive chair of the RNI, and his team successfully opened the blood-brain barrier in a clinical trial with Miller, 54, of Mill Run, Pennsylvania.

By opening the blood-brain barrier, which separates the bloodstream from the brain tissue and restricts medicines, immunotherapy, gene therapy and other therapeutics from entering the brain, researchers hope it can reduce plaques and lessen Millers symptoms.

Rezai and his team previously made waves by being the first in the world to open the hippocampal blood-brain barrier in Alzheimers patients. With Miller, doctors took it a step further by targeting other parts of the brain, namely the parietal lobe, insula and precuneus.

Because our first trial with opening the blood-brain barrier was successful, we were able to treat larger parts of the brain, Rezai said. These other parts of the brain, broadly the parietal lobe, are involved in knowing where you are within your environment and surroundings, and in thinking and processing of memory.

During this study, doctors injected microscopic bubbles into the patients bloodstream, and exposed the bubbles to focused ultrasound from a treatment helmet attached to the MRI, temporarily causing the blood brain barrier to open.

The gradual decline

Forgetting how to return to her work floor was not the only memory setback for Miller. She struggled with number combinations to secure areas of the hospital containing medicines

A coconut cake she made mistakenly wound up in a cupboard. By the time, they found it, it had molded.

And, as an organist at Indian Creek Baptist Church in Mill Run for several years, Miller can no longer play the instrument.

According to the Mayo Clinic, Alzheimer's disease is a progressive disorder that causes brain cells to waste away and die. It is the most common cause of dementia a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently.

Here is the original post:
WVU Rockefeller Neuroscience Institute expands pioneering Alzheimer's treatment to wider region of the brain - DOTmed HealthCare Business News